Physician profile
Thanh Le
NPI 1245537489
$585.07
in general payments reported to CMS, 2019-2025
15 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.71 · 2024: $402 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $86.17 | 2024-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $76.86 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $50.48 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $49.90 | 2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $40.67 | 2024-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $40.17 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $38.64 | 2021 | |
| Abbott Laboratories | $38.06 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $37.65 | 2024 | Trelegy Ellipta |
| Biosense Webster, INC. | $31.99 | 2025 | Carto 3 |
| Dexcom, INC. | $28.58 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $22.74 | 2024 | |
| Esperion Therapeutics, INC. | $17.30 | 2025 | Nexletol |
| Exact Sciences Corporation | $13.79 | 2025 | The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thanh Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.